RIST4721

Phase 2Small molecule

AAristea Therapeutics, Inc.

RIST4721 is one of 101 small molecule programs targeting Palmoplantar Pustulosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Palmoplantar PustulosisActive, not recruiting

Familial Mediterranean FeverActive, not recruiting

Inflammatory ResponseActive, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Palmoplantar PustulosisPhase 2

Active, not recruiting

Familial Mediterranean FeverPhase 2

Active, not recruiting

Inflammatory ResponsePhase 1

Active, not recruiting

Hidradenitis SuppurativaPhase 2

Active, not recruiting

Competition

Competitive Landscape

100 competitors in Hidradenitis Suppurativa

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Phase 3

7 2

Bimzelx

UCB

Phase 3

5 3

Jakafi

Incyte

Phase 3

4 4

Rhapsido

Novartis

Phase 3

3 5

Rinvoq

AbbVie

Phase 3

2 6

Taltz

Povorcitinib

3 8

Lutikizumab

AbbVie

Phase 3

3 9

Saphnelo

AstraZeneca

Phase 2

1 10

Spevigo

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Palmoplantar Pustulosis2 trials

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Terminated·AAristea Therapeutics, Inc.·Phase 2·NCT05194839·79 enrolled

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Completed·AAristea Therapeutics, Inc.·Phase 2·NCT03988335·35 enrolled

Hidradenitis Suppurativa1 trial

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Terminated·AAristea Therapeutics, Inc.·Phase 2·NCT05348681·25 enrolled

Familial Mediterranean Fever1 trial

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

Withdrawn·AAristea Therapeutics, Inc.·Phase 2·NCT05448391

Inflammatory Response1 trial

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

Completed·AAristea Therapeutics, Inc.·Phase 1·NCT04105959·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for RIST4721. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RIST4721 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RIST4721. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aristea Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAristea Therapeutics, Inc.

RIST4721

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Palmoplantar Pustulosis2 trials

Hidradenitis Suppurativa1 trial

Familial Mediterranean Fever1 trial

Inflammatory Response1 trial

References

Drug Info

Quick Facts

Related News